Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
US Department of Justice
Queensland Health
Baxter
Chinese Patent Office
Cantor Fitzgerald
Mallinckrodt
UBS
McKesson
Accenture

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201280

« Back to Dashboard
NDA 201280 describes TRADJENTA, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are thirteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TRADJENTA profile page.

The generic ingredient in TRADJENTA is linagliptin. There are seventeen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin profile page.

Summary for NDA: 201280

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:13
Formulation / Manufacturing:see details

Pharmacology for NDA: 201280

Suppliers and Packaging for NDA: 201280

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRADJENTA
linagliptin
TABLET;ORAL 201280 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0140 0597-0140-30 30 TABLET, FILM COATED in 1 BOTTLE (0597-0140-30)
TRADJENTA
linagliptin
TABLET;ORAL 201280 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0140 0597-0140-61 100 BLISTER PACK in 1 CARTON (0597-0140-61) > 1 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:May 2, 2011TE:RLD:Yes
Patent:► SubscribePatent Expiration:Apr 24, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
Patent:► SubscribePatent Expiration:Apr 24, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
Patent:► SubscribePatent Expiration:Feb 2, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)

Expired Orange Book Patents for NDA: 201280

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
TRADJENTA
linagliptin
TABLET;ORAL201280-001May 2, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Healthtrust
Baxter
US Army
Teva
Novartis
AstraZeneca
Johnson and Johnson
Fish and Richardson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot